High PD‐L1 level of advanced hepatic lymphoepithelioma‐like carcinoma response favorably to lenvatinib plus toripalimab

Zhu, Ying; Dang, Zhuyi; Xu, Hang; Yao, Yuan; Chen, Ye; Li, Zhiping

doi:10.1111/cas.15339

Cited by 6 publications

(4 citation statements)

References 25 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognosis for LEL-CC may improve further if appropriate drug therapy, including immune checkpoint inhibitors, is developed in the future. 28,40 In conclusion, we reported an LEL-CC case without any risk factors such as EBV, viral hepatitis, or cirrhosis. Although such cases are rare, LEL-CC should always be considered in the differential diagnosis of primary liver tumors in middle-aged and Asian women.…”

Section: Therapeutic Advances In Medical Oncologymentioning

confidence: 57%

“…Previous case reports noted that immune checkpoint inhibitors were effective in LELC of the liver and other organs. 40 , 41 The accumulation of cases will presumably lead to the standardization of treatment plans.…”

Section: Discussionmentioning

confidence: 99%

“…The prognosis for LEL-CC may improve further if appropriate drug therapy, including immune checkpoint inhibitors, is developed in the future. 28 , 40 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Lymphoepithelioma-like cholangiocarcinoma not associated with Epstein–Barr virus or hepatitis virus: case report and literature review of 100 reported cases

et al. 2022

View full text Add to dashboard Cite

Lymphoepithelioma-like cholangiocarcinoma (LEL-CC) is a type of lymphoepithelioma-like carcinoma (LELC) and a rare variant of primary liver tumor. Although it is uncommon and only 100 cases have been reported thus far, the number of reports has increased in recent years. LEL-CC reportedly occurs more frequently in Asian women; Epstein–Barr virus (EBV) and hepatitis viruses are both strongly associated with tumor development. Here, we describe a 76-year-old woman who exhibited LEL-CC not associated with EBV or hepatitis virus. She was referred to our department with a 3.0-cm × 2.8-cm tumor in the left lobe of the liver. Based on computed tomography and magnetic resonance imaging findings, the tumor was preoperatively diagnosed as hepatocellular carcinoma. Thus, we performed extended left hepatectomy with caudal lobectomy. Histopathological examinations revealed columnar tumor cells with atypical nuclei that proliferated in a cord-like or glandular tubular pattern with dense lymphocytic infiltration. Immunohistochemical analysis showed negative HepPar-1 and arginase findings, indicating non-hepatocyte origin; however, the biliary-type cytokeratins CK7 and CK19 were detected. Based on these findings, the tumor was identified as LEL-CC. EBV-encoded RNA in situ hybridization findings were negative; the patient’s clinical characteristics were not suggestive of hepatitis virus infection. In conclusion, we suggest that clinicians consider LEL-CC as a differential diagnosis for liver tumors in Asian women, including patients without EBV or hepatitis virus.

show abstract

Section: Therapeutic Advances In Medical Oncologymentioning

confidence: 57%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Lymphoepithelioma-like cholangiocarcinoma not associated with Epstein–Barr virus or hepatitis virus: case report and literature review of 100 reported cases

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Primary hepatic LELC is a special type of liver cancer with a relatively favorable prognosis, although treatment of primary hepatic LELC may be different from highly invasive malignant tumors, such as HCC [13][14][15][16][17]. Thus, pretreatment identification of hepatic LELC is crucial for both therapeutic and prognostic proposes.…”

Section: Discussionmentioning

confidence: 99%

Contrast-Enhanced Ultrasound Features of Primary Hepatic Lymphoepithelioma-Like Carcinoma: Comparison with Hepatocellular Carcinoma

Qin,

Ji,

Zhao

et al. 2024

BIOI

View full text Add to dashboard Cite

Background: Primary hepatic lymphoepithelioma-like carcinoma (LELC) is a malignant tumor with a low incidence, but the number of case reports has increased in recent years. The prognosis of hepatic LELC is better than hepatocellular carcinoma (HCC). The differentiation between hepatic LELC and HCC has clinical value during follow-up treatment. The purpose of our study was to compare contrast-enhanced ultrasound (CEUS) imaging features in patients with hepatic LELC and HCC. Methods: Twelve patients with an average age of 60.1±9.5 years and histopathologically confirmed hepatic LELC were included in the study. Forty-three patients with an average age of 57.4±9.0 years and a histopathological diagnosis of HCC were designated as the control group by means of propensity score matching (1:4). The clinical data, B-mode ultrasound (BMUS), and CEUS features were retrospectively analyzed between patients with hepatic LELC and HCC. Results: The serum a-fetoprotein (58.1% [25/43] vs.16.7% [2/12]; p=0.017) and des-gamma-carboxy prothrombin levels (74.4% [32/43] vs.16.7% [2/12]; p=0.001) were not significantly elevated in patients with hepatic LELCs compared to HCCs. LELCs were mainly hypoechoic based on BMUS, while the echogenicity of HCCs varied (p=0.016). A halo sign was less common in patients with hepatic LELCs than HCCs (16.7% [2/12] vs. 58.1% [25/43]; p=0.011). Of hepatic LELCs, 75% (9/12) had homogeneous hyperenhancement based on CEUS, whereas 58.1% (25/43) of HCCs had heterogeneous hyperenhancement (p=0.004). Early washout was noted in 91.7% (11/12) of hepatic LELCs compared to 46.5% (20/43) of HCCs (p=0.005). Furthermore, hepatic LELCs were more likely to exhibit peripheral rim-like hyperenhancement (83.3% [10/12] vs. 11.6% [5/43]; p < 0.001). Conclusion: BMUS and CEUS are helpful in discriminating between hepatic LELC and HCC. A hypoechoic mass, the rare halo sign, homogeneous hyperenhancement in the arterial phase, higher frequencies of early washout, and peripheral rim-like hyperenhancement are useful ultrasound features that can help differentiate hepatic LELCs from HCCs.

show abstract

Single-center experience in the diagnosis and treatment of lymphoepithelioma-like hepatic carcinoma

Jia

Guo²,

Liu

et al. 2023

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

High PD‐L1 level of advanced hepatic lymphoepithelioma‐like carcinoma response favorably to lenvatinib plus toripalimab

Cited by 6 publications

References 25 publications

Lymphoepithelioma-like cholangiocarcinoma not associated with Epstein–Barr virus or hepatitis virus: case report and literature review of 100 reported cases

Lymphoepithelioma-like cholangiocarcinoma not associated with Epstein–Barr virus or hepatitis virus: case report and literature review of 100 reported cases

Contrast-Enhanced Ultrasound Features of Primary Hepatic Lymphoepithelioma-Like Carcinoma: Comparison with Hepatocellular Carcinoma

Single-center experience in the diagnosis and treatment of lymphoepithelioma-like hepatic carcinoma

Contact Info

Product

Resources

About